Overview
BCTX market data
Price History
No market bars yet for BCTX. This page will populate once the next provider sweep lands.
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for BCTX. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Odette Cancer Centre At Sunnybrook Health Sciences Centre Joined BriaCell’s Ongoing Pivotal Phase 3 Study Of Bria-IMT Plus Immune Checkpoint Inhibitor In Metastatic Breast CancerBenzinga · Jul 16, 2026, 11:36 AM
BriaCell Therapeutics Enters Manufacturing Arrangement With FUJIFILM Biotechnologies To Support Phase 3 Clinical Development And Potential Future Commercial Supply Of Its Allogenic Cell Therapy BRIA-IMTBenzinga · Jul 15, 2026, 11:35 AM
BriaCell Therapeutics Engages Charles River Associates, Kaleio To Explore Commercial Strategy, Market Access Evaluation Of Bria-IMTBenzinga · Jul 7, 2026, 11:40 AM
BriaCell Therapeutics Inks MoU With Uneedle For Continued Use, Commercial Readiness Of Microneedle Technology For Intradermal Administration Of BriaCell’s Bria-IMTBenzinga · Jun 25, 2026, 11:45 AM
BriaCell Therapeutics Q3 EPS $(0.99) Up From $(16.40) YoYBenzinga · Jun 9, 2026, 10:08 PM
BriaCell Therapeutics Presents Positive Clinical Data For Phase 3 Study Of Bria-IMT Plus Immune Checkpoint Inhibitor And Further Analysis Of Phase 2 Data At ASCO Annual Meeting May 29 - June 2Benzinga · Jun 1, 2026, 11:43 AM
Reported Earlier, Cancer Drug Developer BriaCell Prices $4.7M Stock Offering Of 1.45M Shares At $3.25/Share to Fund Operations and ResearchBenzinga · Jun 1, 2026, 7:51 AM
BriaCell Therapeutics Receives Sixth Positive Recommendation From Independent Data Safety Monitoring Board For Its Pivotal Phase 3 Bria-ABC Trial Of Bria-IMT Plus Immune Checkpoint InhibitorBenzinga · May 26, 2026, 11:33 AM
BriaCell Therapeutics Presents Positive Clinical Data From Three Clinical Data Poster Presentations, Three Publication-Only Abstracts At 2026 ASCO Annual MeetingBenzinga · May 22, 2026, 11:35 AM
BriaCell Therapeutics Announces Progress In Developing Bria-OVA+, Next Gen, Personalized, Off-The-Shelf, Cell-Based Immunotherapy For Ovarian CancerBenzinga · May 15, 2026, 11:45 AM